EUVIMEDEUVIMED entdecken
Crossref

Long‐term clinical and endoscopic outcomes of ustekinumab in pediatric Crohn's disease with anti‐tumor necrosis factor failure

Yoko Yamamoto iD, Ichiro Takeuchi iD, Hirotaka Shimizu iD, Hiroki Fujikawa iD, Masanori Toda iD, Eri Miyata iD, Hiroaki To iD, Satoru Nagata iD, Katsuhiro Arai iD

Journal of Gastroenterology and Hepatology · 2025

DOI: 10.1111/jgh.16790 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Yoko Yamamoto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Center for Pediatric Inflammatory Bowel Disease, National Center for Child Health and Development, Tokyo, Japan. Hauptthemen laut MEDLINE: Crohn Disease, Ustekinumab, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Ministry of Health, Labour and Welfare, Japan, Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Only a few studies have reported the long‐term effects of ustekinumab on pediatric Crohn's disease. Therefore, this study aimed to describe the long‐term clinical and endoscopic outcomes of ustekinumab and its safety profile in pediatric‐onset Crohn's disease with anti‐tumor necrosis factor failure.

Methods

Medical records of patients with pediatric‐onset Crohn's disease in whom anti‐tumor necrosis factor therapy failed and ustekinumab treatment was initiated from 2017 to 2022 at a Japanese tertiary children's hospital were retrospectively reviewed. The primary outcome was the continuation rates at weeks 8, 52, and 106. The secondary outcomes were the steroid‐free remission rates at weeks 8, 52, and 106, changes in the Simple Endoscopic Score for Crohn's Disease, and adverse events during follow‐up.

Results

Forty‐three patients were enrolled. The median ages at diagnosis and ustekinumab introduction were 9.7 (interquartile range: 6.7–13.0) years and 13.6 (interquartile range: 8.0–16.0) years. The median follow‐up period was 136 (interquartile range: 102–172) weeks. The continuation rates were 100%, 91%, and 80% at weeks 8, 52, and 106, respectively. The incidence of discontinuation was 6.2% per patient‐year of follow‐up. The steroid‐free remission rates were 44%, 71%, and 80% at weeks 8, 52, and 106, respectively. The Simple Endoscopic Score for Crohn's Disease of patients in clinical remission at the last follow‐up significantly decreased ( P < 0.01), and the safety profile was acceptable.

Conclusions

Ustekinumab appeared effective in maintaining long‐term clinical remission with endoscopic improvement in pediatric‐onset Crohn's disease with anti‐tumor necrosis factor failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseUstekinumabTumor Necrosis Factor-alphaHumansChildMaleFemaleAdolescentRetrospective StudiesTreatment OutcomeTime FactorsRemission InductionTreatment FailureFollow-Up StudiesEndoscopy, Gastrointestinal

Stichwörter der Autor:innen

ChildrenCrohn's diseaseEndoscopic outcomeUstekinumab

Substanzen

UstekinumabTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Division of Gastroenterology, Center for Pediatric Inflammatory Bowel Disease, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan.
  • Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
  • Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

ORCID-Profile: Yoko Yamamoto, Ichiro Takeuchi, Hirotaka Shimizu, Hiroki Fujikawa, Masanori Toda, Eri Miyata, Hiroaki To, Satoru Nagata, Katsuhiro Arai

Förderung

  • Ministry of Health, Labour and Welfare, Japan
  • Ministry of Health, Labour and Welfare

Zitieren

APA

Yamamoto, Y., Takeuchi, I., Shimizu, H., Fujikawa, H., Toda, M., Miyata, E., To, H., Nagata, S., & Arai, K. (2025). Long‐term clinical and endoscopic outcomes of ustekinumab in pediatric Crohn's disease with anti‐tumor necrosis factor failure. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16790

Vancouver

Yamamoto Y, Takeuchi I, Shimizu H, Fujikawa H, Toda M, Miyata E, et al. Long‐term clinical and endoscopic outcomes of ustekinumab in pediatric Crohn's disease with anti‐tumor necrosis factor failure. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.16790

BibTeX
@article{Yamamoto2025,
  author = {Yamamoto, Yoko and Takeuchi, Ichiro and Shimizu, Hirotaka and Fujikawa, Hiroki and Toda, Masanori and Miyata, Eri and To, Hiroaki and Nagata, Satoru and Arai, Katsuhiro},
  title = {Long‐term clinical and endoscopic outcomes of ustekinumab in pediatric Crohn's disease with anti‐tumor necrosis factor failure},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1111/jgh.16790}
}
Kostenlos starten →